T2d clinical trials

Explore recruiting t2d clinical trials.

Recruiting t2d studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

T2d trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

COLchicine and non-enteric coated aspirin in the Cardiovascular Outcomes Trial of patients with Type 2 Diabetes (COLCOT-T2D)

Finland, Portugal, Greece, Denmark, Italy, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 2)

Italy, Croatia, Hungary, Slovakia, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Protocol Title: Efficacy and safety of once-weekly subcutaneous NNC0662-0419 in participants with type 2 diabetes – a dose-finding study

Spain, Hungary, Portugal, Poland, Slovakia, Croatia

Therapeutic exploratory (Phase II) EU CTIS Study details

Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)

Germany, Croatia, Portugal, Hungary, Bulgaria, Romania +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, register-based, randomized, controlled trial comparing dapagliflozin with metformin treatment in early stage type 2 diabetes patients by assessing mortality and macro- and microvascular complications

Sweden

Therapeutic use (Phase IV) EU CTIS Study details

Safety and efficacy of once-weekly subcutaneous and once-daily oral NNC0487-0111 in participants with type 2 diabetes – a dose finding study

Romania, Spain, Poland, Slovakia, Hungary, Croatia +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

T2d trials by city

T2d in Toronto T2d in Vancouver T2d in Montreal T2d in Calgary T2d in Edmonton T2d in Ottawa T2d in Winnipeg T2d in Quebec City T2d in Hamilton T2d in Kitchener T2d in London T2d in Halifax T2d in New York T2d in Los Angeles T2d in Chicago T2d in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease